Clinigen Group plc, of Burton-upon-Trent, U.K., and Eiger BioPharmaceuticals Inc., of Palo Alto, Calif., are launching a worldwide managed access program for Eiger's lonafarnib, an inhibitor of farnesyltransferase for patients with progeria and progeroid laminopathies. Eiger plans to file an NDA for the drug this year.